Acquiring Company
BioNTech
Acquired Company
CureVac
MainzTübingenBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsDescription
BioNTech has successfully acquired CureVac, leading to the conversion of CureVac stock into BioNTech shares at a rate of 0.0520 BNTX shares per CVAC share. This all-stock transaction was announced on June 12, 2025, with an implied equity value of USD 1.25 billion. Following the merger, CureVac will close its Tübingen site in 2027 as part of the integration into the BioNTech Group.
Fundz sees it the moment BioNTech makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired CureVac?
CureVac was acquired by BioNTech, based in Mainz. The deal was reported on October 4, 2026. BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases. BioNTech is publicly traded (BNTX) and operates in Biotechnology.
When did BioNTech acquire CureVac?
BioNTech's acquisition of CureVac was reported on October 4, 2026. BioNTech has successfully acquired CureVac, leading to the conversion of CureVac stock into BioNTech shares at a rate of 0.0520 BNTX shares per CVAC share. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does CureVac do?
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. It is privately held, operating in Biotechnology, and is based in Tübingen.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.